To access this element change to forms mode OFF
Grant Award View - GA268548
antiCD20 treatment to rationalise the use of IV/SC-IG in CIDP
GA ID:
GA268548
Agency:
Department of Health and Aged Care
Approval Date:
7-Apr-2022
Publish Date:
4-Oct-2022
Category:
Medical Research
Grant Term:
7-Apr-2022 to 31-Mar-2027
Value (AUD):
$2,891,769.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
antiCD20 treatment to rationalise the use of IV/SC-IG in CIDP
Purpose:
We will conduct the first trial in an uncommon, but expensive to treat, peripheral nerve disease, to determine whether targeting lymphocytes with a monoclonal antibody therapy will allow better treatment and less use of the very expensive drug currently used, Immunoglobulin. With this we will evaluate available possible marker of disease and discover new ones to help tailor treatments to individual patient needs in this disease.
GO ID:
GO Title:
MRFF – PPHRI – 2021 Optimising the Clinical Use of Immunoglobulins Grant Opportunity
Internal Reference ID:
2022/MRF2017572
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA